Skip to main content
SpringerLink
Log in

Implementing Adaptive Designs: Logistical and Operational Considerations

  • Adaptive Design
  • Published:
Drug information journal : DIJ / Drug Information Association Aims and scope Submit manuscript

Abstract

The objective of this article is to support alogistical and operational feasibility analysis: given the research question and the environment in which we work, is it appropriate to consider an adaptive design, and are we sufficiently well prepared to deploy successfully?

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Maca J, Bhattacharya S, Dragalin V, Gallo P, Krams M. Adaptive seamless phase II/III designs—background, operational aspects, and examples. Drug Inf J. 2006;40:463–474.

    Article  Google Scholar 

  2. Grieve AP, Krams M. ASTIN: a Bayesian adaptive dose-response trial in acute stroke. Clin Trials. 2005;2:340–351.

    Article  Google Scholar 

  3. Berry DA. Statistical innovations in oncology. In Holland J, Frei E, Kufe D, et al., eds. Cancer Medicine. 6th ed. London: Decker; 2003:465–487.

    Google Scholar 

  4. Dragalin V, Fedorov V. Adaptive designs for dose-finding based on efficacy-toxicity response. J Stat Plann Inference. 2006;136:1800–1823.

    Article  Google Scholar 

  5. Thall PF, Cook JD. Dose-finding based on efficacy-toxicity trade-offs. Biometrics. 2004;60:684–693.

    Article  Google Scholar 

  6. Gaydos B, Bedding A, Berry D, et al. Adaptive dose-response finding studies. Drug Inf J. 2006;40:451–461.

    Article  Google Scholar 

  7. Ellenberg SE, Fleming TR, DeMets DL. Data Monitoring Committees in Clinical Trials: A Practical Perspective. Chichester, UK: Wiley; 2002.

    Book  Google Scholar 

  8. US Food and Drug Administration. Guidance for Clinical Trial Sponsors on the Establishment and Operation of Clinical Trial Data Monitoring Committees. Rockville, MD: US Food and Drug Administration; 2006.

    Google Scholar 

  9. Committee for Medicinal Products for Human Use. Guideline on Data Monitoring Committees. London: EMEA; 2005.

    Google Scholar 

  10. Gallo P. Regulatory confidentiality issues for adaptive design trials. Drug Inf J. 2006;40:445–450.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. GlaxoSmithKline, USA

    Judith A. Quinlan

  2. Wyeth, USA

    Michael Krams (Assistant Vice President)

Authors
  1. Judith A. Quinlan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Krams
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Quinlan, J.A., Krams, M. Implementing Adaptive Designs: Logistical and Operational Considerations. Ther Innov Regul Sci 40, 437–444 (2006). https://doi.org/10.1177/216847900604000409

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/216847900604000409

Key Words

Search

Navigation